AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 NOV 8 - (NewsRx.com & NewsRx.net) -- A presentation at the Annual Meeting of the International Society for Interferon and Cytokine Research in Cleveland, Ohio, by scientists from the Institute of Human Virology (IHV) and CEL-SCI suggests a potentially effective new immunotherapy treatment for HIV infected women with human papillomavirus (HPV)-induced cervical dysplasia.
In the U.S. alone, about 120,000 to 140,000 women have this disease and are in need of effective therapy.
At the conference it was reported that all five patients treated thus far at the lowest dose of Multikine in an ongoing dose escalating study showed clinical improvement by colposcopic (stereoscopic, binocular magnification of the cervix under a focused beam of light) examination. Three out of four patients had no evidence of dysplasia on biopsy seven to eight weeks after the final injection. Biopsies on the remaining volunteer showed no apparent changes in her dysplasia. One patient was lost to follow-up.
All of the patients tolerated the injections well and without any associated serious adverse reactions. Enrollment at this dose level is completed. The evaluation of Multikine at a higher dose is ongoing as a preliminary to the initiation of a pivotal clinical trial in 2002.
The presentation was entitled, "Immunotherapy with leukocyte interleukin, injection for human papillomavirus (HPV) induced cervical dysplasia in HIV patients," and was authored by G. Taylor and colleagues, of the Institute of Human Virology, the University of Maryland, CEL-SCI Corporation, and the U.S. National Institute of Allergy and Infectious Diseases (NIAID). This study was supported in part by a MIPS (Maryland Industrial Partnership) grant from the State of Maryland, a program designed to foster cooperation between researchers/clinicians and industry.
HPV infection is also a leading health problem in non-HIV infected American college age women. A large concern among women who have HPV-induced cervical dysplasia is that the surgical procedures required to treat cervical dysplasia have a high morbidity rate ranging from cervical incompetence to hysterectomy and the inability to bear children. Furthermore, cervical cancer is the second leading cause of cancer death in women worldwide.
Geert Kersten, CEL-SCI said, "The results we have seen ...